Clinical trial
A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Clinical Study of Eslicarbazepine Acetate in Post-Herpetic Neuralgia
NCT01124097 is registered in ClinicalTrials.gov with Bial - Portela C S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Clinical Study of Eslicarbazepine Acetate in Post-Herpetic Neuralgia
- Lead sponsor
- Bial - Portela C S.A.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- September 30, 2010
- Completion date
- April 30, 2012
- Enrollment
- 240 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
post herpetic neuralgia